首页> 外文期刊>Blood pressure. >Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
【24h】

Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.

机译:氯沙坦基于血管紧张素II受体阻滞剂的治疗对先前治疗的高血压患者左心室肥大和体型的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: The 2003 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines recommend angiotensin II receptor antagonists (AIIRAs) as a first-line therapy in hypertensives with left ventricular hypertrophy (LVH). AIM: We investigated the long-term effects of an AIIRA-based therapy on left ventricular (LV) structure and geometry in previously, unsatisfactorily treated essential hypertensive patients. METHODS: Sixty-eight consecutive patients referred to our hypertension hospital outpatient clinic with: (i) LVH (LV mass index, LVMI 51 g/m(2.7) in men and 47 g/m(2.7) in women), (ii) uncontrolled clinic blood pressure (BP140 and/or 90 mmHg) and (iii) antihypertensive therapy not including angiotensin-converting enzyme (ACE) inhibitors or AIIRAs were selected for this study. Two-dimensionally guided M-mode echocardiograms were carried out at baseline and after 6, 12, 18 and 24 months of follow-up. In all patients, losartan (50-100 mg/day, mean dose 82 mg/day) was added as firststep to the previous therapy. Additional drugs, tailored to the single patient, were added, if necessary, to achieve target BP values (<140/90 mmHg). RESULTS: Overall, 59 patients completed the study with the primary efficacy measurements (LVMI) at all appropriate times. A significant reduction in both clinic systolic BP and diastolic BP was found across the entire period of study respect to baseline (-17/10, -22/12, -24/13 and -26/14 mmHg at 6, 12, 18 and 24 months, p < 0.001 respectively), leading to target clinic BP in 75.6% of cases. LVMI was significantly lower after 1 year of treatment (-11 +/- 12%, p < 0.05) with a further significant reduction at the end of treatment (-22 +/- 18%, p < 0.01). The proportion of patients achieving normalization of LVMI was 47.4% and more importantly, the prevalence of concentric LVH fell from 38.9% to 6.7% (p < 0.01). CONCLUSIONS: Our findings indicate that long-term intensive treatment based on the AIIRA losartan induced a normalization of LVH in about 50% of patients and more importantly caused an almost complete regression of concentric LVH, the most dangerous adaptive pattern. The transition from concentric to normal or eccentric LV geometry may have in these high-risk patients a favourable prognostic implication in addition to the recognized positive effect of reducing LVMI.
机译:背景:2003年欧洲高血压学会/欧洲心脏病学会(ESH / ESC)指南推荐将血管紧张素II受体拮抗剂(AIIRAs)作为左心室肥大(LVH)高血压的一线治疗。目的:我们调查了先前未得到令人满意治疗的原发性高血压患者基于AIIRA的治疗对左心室(LV)结构和几何形状的长期影响。方法:连续68例患者转诊至我们的高血压医院门诊,其病情包括:(i)LVH(LV质量指数,男性LVMI 51 g / m(2.7),女性47 g / m(2.7)),(ii)本研究选择不受控制的临床血压(BP140和/或90 mmHg)和(iii)不包括血管紧张素转换酶(ACE)抑制剂或AIIRA的降压治疗。在基线以及随访6、12、18和24个月后进行二维引导的M型超声心动图。在所有患者中,氯沙坦(50-100毫克/天,平均剂量82毫克/天)是先前治疗的第一步。如果需要,可添加针对单个患者的其他药物,以达到目标BP值(<140/90 mmHg)。结果:共有59例患者在所有合适的时间完成了主要疗效测量(LVMI)的研究。在整个研究期间,相对于基线(17/10,-22 / 12,-24 / 13和-26/14 mmHg在6、12、18和23 mmHg时),临床收缩压和舒张压均显着降低。 24个月,分别为p <0.001),导致75.6%的患者达到目标临床BP。 LVMI在治疗1年后显着降低(-11 +/- 12%,p <0.05),在治疗结束时进一步显着降低(-22 +/- 18%,p <0.01)。 LVMI正常化的患者比例为47.4%,更重要的是,同心LVH的患病率从38.9%下降至6.7%(p <0.01)。结论:我们的研究结果表明,基于AIIRA氯沙坦的长期强化治疗在大约50%的患者中引起LVH正常化,更重要的是导致同心LVH几乎完全消退,这是最危险的适应性模式。在这些高风险患者中,从同心LV几何形状向正常或偏心LV几何形状的转变可能除了具有公认的降低LVMI的积极作用外,还具有良好的预后意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号